
Celgene appoints European haematology and oncology head
pharmafile | May 7, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Celgene, Michael Zaiac
Swiss-based Celgene International Sàrl has appointed Michael Zaiac to the position of vice president of medical affairs for its European haematology and oncology business.
Zaiac joins the US firm’s European wing from GSK, where he most recently was the franchise medical head for immuno-inflammation and infectious diseases.
He takes to Celgene experience and knowledge in hematology and oncology, and before joining the industry served for several years as senior house officer in the UK in general, orthopaedic and cardiothoracic surgery – as well as in the general and vascular surgery and surgical oncology in Germany.
Marie-France Tschudin who is the corporate VP of its haematology and oncology unit says: “I am really pleased to have Michael on board to head up our haematology/oncology medical affairs team. This is a really exciting time for Celgene in EMEA. His expertise in this area will give us the strong support we need at this fast-moving time.”
Related Content

NICE recommends Celgene’s REVLIMID for multiple myeloma
NICE has issued a Final Appraisal Document (FAD) recommending Celgene’s REVLIMID (lenalidomide) as maintenance treatment …

NICE opts to reject Celgene’s Revlimid for newly diagnosed multiple myeloma after an autologous stem cell transplant
It has emerged that NICE has opted to reject Celgene’s Revlimid (lenalidomide) for the maintenance …

NICE recommends Celgene’s Revlimid combo for follicular lymphoma
NICE has chosen to recommend Celgene’s Revlimid (lenalidomide) for use on the NHS, it has …






